Plain-English translation of NCT06953999 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pancreatic Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large research study testing whether adding Ivonescimab—a new type of cancer-fighting medication—and/or another medication called AK117 to standard chemotherapy works better than chemotherapy alone for people with advanced pancreatic cancer. About 1,000 patients will participate. Some patients will receive both new medications, some will receive just one, and some will receive a placebo (a dummy treatment), all combined with the same chemotherapy drugs.
Pancreatic cancer is very difficult to treat, and even with chemotherapy, outcomes for patients with advanced disease remain poor. Researchers believe that adding this medication and/or the other treatment might help the chemotherapy work more effectively and improve survival for patients with this serious diagnosis.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of three treatment groups—each receiving chemotherapy plus different combinations of the new medications or placebos. You will receive treatment through infusions (IV) and possibly pills, with regular clinic visits for checkups, blood tests, and imaging scans to see how you're responding. The study will continue for as long as the treatment is helping you and you can tolerate it safely.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
China